Search
forLearn
5 / 801 resultsResearch
5 / 1000+ resultsresearch S100A8 induces cyclophosphamide-induced alopecia via NCF2/NOX2-mediated ferroptosis
Blocking S100A8 can reduce chemotherapy-induced hair loss.
research Structure of human type II 5 alpha-reductase gene.
The human type II 5α-reductase gene, linked to certain male health conditions, has a specific structure and low similarity to other related genes.
research Tissue-Engineered Skin Preserving the Potential of Epithelial Cells to Differentiate into Hair After Grafting
Tissue-engineered skin can support hair growth after grafting, especially with mouse-derived dermis.
research Considerations in the choice of a skin donor site for harvesting keratinocytes containing a high proportion of stem cells for culture in vitro
P-auricular skin is the best donor site for high stem cell content in keratinocyte cultures.
research Suppression of eukaryotic initiation factor 4E prevents chemotherapy-induced alopecia
Suppressing eIF4E can prevent hair loss from chemotherapy.
Community Join
5 / 1000+ resultscommunity Pyrilutamide PHASE 2 Results just one months to go. Are you excited???🤩
Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.
community How much do you pay for finasteride in Europe?
Finasteride prices vary widely across Europe, with some users opting to buy 5mg tablets and split them to save money. Many find 1mg tablets more expensive, and some suggest importing from countries like India for cheaper options.
community Lost density 60% all over scalp in 120 days (4months)
A user lost 60% hair density in 4 months, started finasteride and microneedling, and has greasy, flaky, yellowish scalp. They are awaiting biopsy results, and another user suggested trying ketoconazole shampoo.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.